Literature DB >> 24758560

Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice.

Tsuyoshi Yamamoto1, Naoko Fujii, Hidenori Yasuhara, Shunsuke Wada, Fumito Wada, Naoya Shigesada, Mariko Harada-Shiba, Satoshi Obika.   

Abstract

The multiple-turnover ability of a series of locked nucleic acid (LNA)-based antisense oligonucleotides (AONs) in the RNase H-mediated scission reaction was estimated using a newly developed cell-free reaction system. We determined the initial reaction rates of AONs under multiple-turnover conditions and found that among 24 AONs tested, AONs with melting temperatures (Tm) of 40°C-60°C efficiently elicit multiple rounds of RNA scission. On the other hand, by measuring Tm with two 10-mer RNAs partially complementary to AONs as models of cleaved 5' and 3' fragments of mRNA, we found that AONs require adequate binding affinity for efficient turnover activities. We further demonstrated that the efficacy of a set of 13-mer AONs in mice correlated with their turnover efficiency, indicating that the intracellular situation where AONs function is similar to multiple-turnover conditions. Our methodology and findings may provide an opportunity to shed light on a previously unknown antisense mechanism, leading to further improvement of the activity and safety profiles of AONs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24758560      PMCID: PMC4106378          DOI: 10.1089/nat.2013.0470

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  25 in total

1.  Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription.

Authors:  Marcin Nowotny; Sergei A Gaidamakov; Rodolfo Ghirlando; Susana M Cerritelli; Robert J Crouch; Wei Yang
Journal:  Mol Cell       Date:  2007-10-26       Impact factor: 17.970

2.  N-Methyl substituted 2',4'- BNANC: a highly nuclease-resistant nucleic acid analogue with high-affinity RNA selective hybridization.

Authors:  Kazuyuki Miyashita; S M Abdur Rahman; Sayori Seki; Satoshi Obika; Takeshi Imanishi
Journal:  Chem Commun (Camb)       Date:  2007-07-09       Impact factor: 6.222

3.  Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements.

Authors:  Anna-Karin Sohlenius-Sternbeck
Journal:  Toxicol In Vitro       Date:  2006-06-29       Impact factor: 3.500

4.  Design of antisense oligonucleotides stabilized by locked nucleic acids.

Authors:  Jens Kurreck; Eliza Wyszko; Clemens Gillen; Volker A Erdmann
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

5.  Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes.

Authors:  S T Crooke; K M Lemonidis; L Neilson; R Griffey; E A Lesnik; B P Monia
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

6.  Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy)aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal models.

Authors:  Thazha P Prakash; Andrew Siwkowski; Charles R Allerson; Michael T Migawa; Sam Lee; Hans J Gaus; Chris Black; Punit P Seth; Eric E Swayze; Balkrishen Bhat
Journal:  J Med Chem       Date:  2010-02-25       Impact factor: 7.446

7.  Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes.

Authors:  Erich Koller; Thomas M Vincent; Alfred Chappell; Soma De; Muthiah Manoharan; C Frank Bennett
Journal:  Nucleic Acids Res       Date:  2011-02-23       Impact factor: 16.971

8.  Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection.

Authors:  Y Zhang; Z Qu; S Kim; V Shi; B Liao; P Kraft; R Bandaru; Y Wu; L M Greenberger; I D Horak
Journal:  Gene Ther       Date:  2010-12-23       Impact factor: 5.250

9.  Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents.

Authors:  C A Stein; J Bo Hansen; Johnathan Lai; SiJian Wu; Anatoliy Voskresenskiy; Anja Høg; Jesper Worm; Maj Hedtjärn; Naira Souleimanian; Paul Miller; Harris S Soifer; Daniella Castanotto; Luba Benimetskaya; Henrik Ørum; Troels Koch
Journal:  Nucleic Acids Res       Date:  2009-10-23       Impact factor: 16.971

10.  Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice.

Authors:  Tsuyoshi Yamamoto; Mariko Harada-Shiba; Moeka Nakatani; Shunsuke Wada; Hidenori Yasuhara; Keisuke Narukawa; Kiyomi Sasaki; Masa-Aki Shibata; Hidetaka Torigoe; Tetsuji Yamaoka; Takeshi Imanishi; Satoshi Obika
Journal:  Mol Ther Nucleic Acids       Date:  2012-05-15       Impact factor: 10.183

View more
  11 in total

1.  A novel dual lock method for down-regulation of genes, in which a target mRNA is captured at 2 independent positions by linked locked nucleic acid antisense oligonucleotides.

Authors:  Ryohei Takata; Gouki Makado; Ayaka Kitamura; Hajime Watanabe; Tadashi Wada
Journal:  RNA Biol       Date:  2016-02-18       Impact factor: 4.652

Review 2.  Pharmacokinetics and Proceedings in Clinical Application of Nucleic Acid Therapeutics.

Authors:  Markus Herkt; Thomas Thum
Journal:  Mol Ther       Date:  2020-11-12       Impact factor: 11.454

3.  Ca2+ enrichment in culture medium potentiates effect of oligonucleotides.

Authors:  Shin-Ichiro Hori; Tsuyoshi Yamamoto; Reiko Waki; Shunsuke Wada; Fumito Wada; Mio Noda; Satoshi Obika
Journal:  Nucleic Acids Res       Date:  2015-06-22       Impact factor: 16.971

4.  LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts.

Authors:  Aleksander Touznik; Rika Maruyama; Kana Hosoki; Yusuke Echigoya; Toshifumi Yokota
Journal:  Sci Rep       Date:  2017-06-16       Impact factor: 4.379

5.  Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice.

Authors:  Peter H Hagedorn; Malene Pontoppidan; Tina S Bisgaard; Marco Berrera; Andreas Dieckmann; Martin Ebeling; Marianne R Møller; Heidi Hudlebusch; Marianne L Jensen; Henrik F Hansen; Troels Koch; Morten Lindow
Journal:  Nucleic Acids Res       Date:  2018-06-20       Impact factor: 16.971

6.  Highly efficient silencing of microRNA by heteroduplex oligonucleotides.

Authors:  Kotaro Yoshioka; Taiki Kunieda; Yutaro Asami; Huijia Guo; Haruka Miyata; Kie Yoshida-Tanaka; Yumiko Sujino; Wenying Piao; Hiroya Kuwahara; Kazutaka Nishina; Rintaro Iwata Hara; Tetsuya Nagata; Takeshi Wada; Satoshi Obika; Takanori Yokota
Journal:  Nucleic Acids Res       Date:  2019-08-22       Impact factor: 16.971

7.  Targeting Repeated Regions Unique to a Gene Is an Effective Strategy for Discovering Potent and Efficacious Antisense Oligonucleotides.

Authors:  Lykke Pedersen; Peter Hagedorn; Jonas Vikeså; Signe Tang Karlsen; Pia Særmark; Troels Koch; Morten Lindow
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-15       Impact factor: 8.886

8.  Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro.

Authors:  Takenori Shimo; Keisuke Tachibana; Kiwamu Saito; Tokuyuki Yoshida; Erisa Tomita; Reiko Waki; Tsuyoshi Yamamoto; Takefumi Doi; Takao Inoue; Junji Kawakami; Satoshi Obika
Journal:  Nucleic Acids Res       Date:  2014-06-16       Impact factor: 16.971

Review 9.  Development of Antisense Drugs for Dyslipidemia.

Authors:  Tsuyoshi Yamamoto; Fumito Wada; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2016-07-27       Impact factor: 4.928

10.  Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties.

Authors:  Natalia Papargyri; Malene Pontoppidan; Mikael R Andersen; Troels Koch; Peter H Hagedorn
Journal:  Mol Ther Nucleic Acids       Date:  2019-12-18       Impact factor: 8.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.